Building an interventional pain OBL from scratch
Starting an interventional pain OBL is more accessible than most realize. Here’s the rate research and feasibility framework.
Starting an interventional pain OBL is more accessible than most realize. Here’s the rate research and feasibility framework.
Pain practice AI is moving toward fluoro-procedure dictation and coding. Here’s the working stack.
Pain ASC owners often own the building. Here’s how to layer that with a personal real estate portfolio.
Procedural pain K-1 income shields differently than pure W-2. Here’s the optimization stack.
Interventional pain has the second-cleanest OBL economics in medicine. Here’s the rate data, the proforma, and the regulatory landscape.
Dermatology AI has the most validation data in lesion detection. Here’s the working directory.
Dermatology compensation supports aggressive real estate strategies. Here’s the playbook.
Insurance derm + cash aesthetics + Mohs = three different revenue streams with three different tax treatments.
Mohs surgery and dermpath are the highest-margin lines in dermatology. Here’s how to evaluate adding them to a practice.
Cash-pay aesthetics is the highest-margin practice model in dermatology. Here’s the structure, the regulatory landscape, and the operating economics.